Trial Profile
A Phase II Study of Immunotherapy With Durvalumab and Tremelimumab in Combination With Capecitabine or Without Capecitabine in Adjuvant Situation for Biliary Tract Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Durvalumab; Tremelimumab
- Indications Biliary cancer; Cholangiocarcinoma
- Focus Therapeutic Use
- 22 Jan 2024 Planned End Date changed from 1 Dec 2024 to 30 Jun 2025.
- 22 Jan 2024 Planned primary completion date changed from 1 Sep 2024 to 31 Dec 2024.
- 22 Jan 2024 Status changed from recruiting to active, no longer recruiting.